Decreased clonogenic capacity of U87MG and U251MG GB cells following treatment with SHG-44 and cis-platin at equal concentrations. by Denis Mustafov (19137870)

Distribution of the same ingredient across different IDDSI levels (Percentages and frequencies) and statistical significance analysis (Chi-square analysis). by Muxi Chen (9294270)

Subjects:

Parasite burden is significantly decreased in the small intestine of <i>taiep</i> infected rats. by Karen Elizabeth Nava-Castro (6940340)

Summary results of the logistic regression model M2-12 including the significant two-way interactions to maximise loglikelihood. by Dennis Ochola (11626912)

Photoreceptors undergo substantial changes in TF activity during aging. by Juan Jauregui-Lozano (12024868)

“…PCA of aging ATAC-seq samples based on the read distribution over binned genome. …”

Significantly Increased Specific Discharge Capacitance at Carbon Fibers Created via Architected Ultramicropores by Ying Zheng (170527)

Significantly Increased Specific Discharge Capacitance at Carbon Fibers Created via Architected Ultramicropores by Ying Zheng (170527)

Significantly Increased Specific Discharge Capacitance at Carbon Fibers Created via Architected Ultramicropores by Ying Zheng (170527)

Significantly Increased Specific Discharge Capacitance at Carbon Fibers Created via Architected Ultramicropores by Ying Zheng (170527)

Distribution of different ingredients at the same IDDSI level (Percentage and frequency) and statistical significance analysis (Chi-square test)^b'*'. by Muxi Chen (9294270)

Subjects:

Significant clusters of open defecation spatial window in Ethiopia, EDHS 2016 plotted using ArcMap 10.7. by Daniel Gashaneh Belay (12334351)

Subjects:

Treatment with SMIFH2 decreases the actin level in oocytes and impairs spindle formation. by Hak-Cheol Kim (716627)

“…Treatment with SMIFH2 decreases the cortical actin level in maturing mouse oocytes. …”

Trends in the days of sulfamethoxazole-trimethoprim therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in in-hospital mortality by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

Subjects:

Trends in the days of cefalexin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the days of quinolone therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the length of hospital stay by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

Subjects:

Trends in the days of macrolides therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the days of amoxicillin and amoxicillin-clavulanate therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the days of third-generation cephalosporin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects: